Original language | English |
---|---|
Pages (from-to) | 664-668 |
Number of pages | 5 |
Journal | British Journal of Haematology |
Volume | 183 |
Issue number | 4 |
DOIs | |
Publication status | Published - Nov 2018 |
All Science Journal Classification (ASJC) codes
- Hematology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation. / Takamatsu, Hiroyuki; Wee, Rachel K.; Zaimoku, Yoshitaka; Murata, Ryoichi; Zheng, Jianbiao; Moorhead, Martin; Carlton, Victoria E.H.; Kong, Katherine A.; Takezako, Naoki; Ito, Shigeki; Miyamoto, Toshihiro; Yokoyama, Kenji; Matsue, Kosei; Sato, Tsutomu; Kurokawa, Toshiro; Yagi, Hideo; Terasaki, Yasushi; Ohata, Kinya; Matsumoto, Morio; Yoshida, Takashi; Faham, Malek; Nakao, Shinji.
In: British Journal of Haematology, Vol. 183, No. 4, 11.2018, p. 664-668.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation
AU - Takamatsu, Hiroyuki
AU - Wee, Rachel K.
AU - Zaimoku, Yoshitaka
AU - Murata, Ryoichi
AU - Zheng, Jianbiao
AU - Moorhead, Martin
AU - Carlton, Victoria E.H.
AU - Kong, Katherine A.
AU - Takezako, Naoki
AU - Ito, Shigeki
AU - Miyamoto, Toshihiro
AU - Yokoyama, Kenji
AU - Matsue, Kosei
AU - Sato, Tsutomu
AU - Kurokawa, Toshiro
AU - Yagi, Hideo
AU - Terasaki, Yasushi
AU - Ohata, Kinya
AU - Matsumoto, Morio
AU - Yoshida, Takashi
AU - Faham, Malek
AU - Nakao, Shinji
N1 - Funding Information: We would like to acknowledge Drs Yoshiyasu Ogawa and Nor-iko Kobayashi of LSI Medience Corporation and Ms Rie Oumi and Ms Tomoko Tanaka of Kanazawa University for their technical assistance. This research project was supported by the following grants: a Grant-in-Aid for Scientific Research (C) (15K08644), Research Award from the Mitsui Life Social Welfare Foundation, Research Award from the International Myeloma Foundation Japan, and Research Award from the Hokkoku Foundation for Cancer Research (H.T.). This study was supported in part by research funding from Adaptive Biotechnologies (J.Z, M.M, V.E.H.C, K.A.K, M.F.). Funding Information: H.T. received research funding from Takeda and Fujimoto, and honoraria from Celgene and Janssen. S.I. received research funding from Bristol-Myers Squibb and honoraria from Celgene. K.Y. received research funding from Takeda and honoraria from Celgene. J. Z., M.M., V. E. H. C., K. A. K. and M.F. are employees of Adaptive Biotechnologies. The remaining authors declare no competing financial interests.
PY - 2018/11
Y1 - 2018/11
UR - http://www.scopus.com/inward/record.url?scp=85038881461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038881461&partnerID=8YFLogxK
U2 - 10.1111/bjh.15002
DO - 10.1111/bjh.15002
M3 - Letter
C2 - 29270982
AN - SCOPUS:85038881461
VL - 183
SP - 664
EP - 668
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 4
ER -